Knight follows BioMarin's lead; seeks voucher buyer
This article was originally published in Scrip
Executive Summary
After the $67.5m bundle of cash BioMarin Pharmaceutical hauled in from selling its priority review voucher (PRV) to Regeneron and its partner Sanofi last month, Knight Therapeutics has decided the market was ripe for the pickings – hiring a global investment banking firm to do the same.